Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases.

Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases.

The treatment of renal limited systemic vasculitis usually involves a combination of cytotoxic drugs and steroids. As shown by randomised prospective controlled trial, plasmapheresis may be of additional benefit for the management of patients with renal involvement severe enough to require dialysis...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Elliott, J, Lockwood, C, Hale, G, Waldmann, H
Format:	Journal article
Język:	English
Wydane:	1998

Podobne zapisy

Monoclonal-antibody therapy in systemic vasculitis.
od: Mathieson, P, i wsp.
Wydane: (1990)

MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
od: Mathieson, P, i wsp.
Wydane: (1990)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
od: Lockwood, C, i wsp.
Wydane: (1993)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
od: Lockwood, C, i wsp.
Wydane: (1993)

MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
od: Isaacs, J, i wsp.
Wydane: (1993)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
od: Zachary S. Wallace, i wsp.
Wydane: (2019-12-01)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS
od: Adu, D, i wsp.
Wydane: (1994)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
od: Lockwood, C, i wsp.
Wydane: (1995)

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.
od: Lockwood, C, i wsp.
Wydane: (1996)

Relapse Predictors in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
od: Katarzyna Wawrzycka-Adamczyk, i wsp.
Wydane: (2024-08-01)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
od: Alan D. Salama
Wydane: (2020-01-01)

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
od: Bindon, C, i wsp.
Wydane: (1988)

Updates in ANCA-associated vasculitis
od: Carolyn Ross, i wsp.
Wydane: (2022-07-01)

Epidemiology of ANCA associated vasculitis
od: Wenche Koldingsnes, i wsp.
Wydane: (2008-01-01)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
od: McLaren, J, i wsp.
Wydane: (2001)

The Diagnosing Challenge of a Positive ANCA Vasculitis in the Paediatric Age
od: Clara Preto, i wsp.
Wydane: (2017-01-01)

Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
od: Mandy Sowa, i wsp.
Wydane: (2014-01-01)

Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis
od: Daisuke Tsukui, i wsp.
Wydane: (2021-01-01)

Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
od: Jayne, D, i wsp.
Wydane: (1999)

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.
od: Jayne, DR, i wsp.
Wydane: (2000)

Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.
od: Hale, G, i wsp.
Wydane: (1985)

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, i wsp.
Wydane: (2013)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, i wsp.
Wydane: (2012)

Explaining fatigue in ANCA-associated vasculitis
od: Basu, N, i wsp.
Wydane: (2013)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, i wsp.
Wydane: (2012)

Cutaneous manifestations of ANCA-associated vasculitis
od: Chiesafuxench, Z, i wsp.
Wydane: (2016)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i wsp.
Wydane: (2008)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, i wsp.
Wydane: (2010)

The involvement of NETs in ANCA-associated vasculitis
od: Satoka Shiratori-Aso, i wsp.
Wydane: (2023-09-01)

Vasculitis ANCA y esclerosis sistémica
od: Maite Hurtado, i wsp.
Wydane: (2016-11-01)

Complement Inhibition in ANCA-Associated Vasculitis
od: Vladimir Tesar, i wsp.
Wydane: (2022-07-01)

Individualization of the ANCA associated vasculitis treatment
od: Zbigniew Zdrojewski
Wydane: (2014-09-01)

Update of Management of ANCA-Associated Vasculitis
od: Hoi San Tang, i wsp.
Wydane: (2021-12-01)

Advantages of rat monoclonal antibodies.
od: Clark, M, i wsp.
Wydane: (1983)

Correction: Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA.
od: Mandy Sowa, i wsp.
Wydane: (2015-01-01)

Correction: simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.
od: PLOS ONE Staff
Wydane: (2015-01-01)

Anti-plasminogen antibodies in ANCA-associated vasculitis: An optimized anti-plasminogen assay.
od: Arda Göçeroğlu, i wsp.
Wydane: (2018-01-01)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1994)

Interest of a Kidney Biopsy to Rule out ANCA-Associated Renal Vasculitis in Glomerulonephritis Patients with a Positive ANCA
od: Florian Garo, i wsp.
Wydane: (2022-04-01)